\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[ngerman,english]{babel}



\usepackage{float}








\begin{document}

\title{Benefits of sacubitril/valsartan use in patients with chronic heart
failure after cardiac valve surgery: a single-center retrospective
study.}



\author[1]{Jian Zheng}%
\author[2]{Qingsong Wu}%
\author[2]{Qianzhen Li}%
\author[2]{mirong tang}%
\author[2]{zhihuang qiu}%
\author[2]{liangwan chen}%
\affil[1]{Department of Pharmacy the First Affiliated Hospital of Fujian Medical University Fuzhou Fujian P RChina}%
\affil[2]{Department of Cardiovascular Surgery Union Hospital Fujian Medical University Fuzhou Fujian P RChina}%


\vspace{-1em}



  
  \date{May 20, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
\textbf{Objective:} To evaluate the efficacy of sacubitril/valsartan for
the treatment of patients with chronic heart failure (CHF) after cardiac
valve surgery (CVS). \textbf{Methods:} Data of 259 patients who
underwent CVS due to organic heart disease, and who were admitted to the
hospital with CHF from January 2018 to December 2020, were collected.
The patients were divided into Group A (treatment with
sacubitril/valsartan) and Group B (treatment without
sacubitril/valsartan). The duration of treatment and follow-up was 6
months. Prior-treatment clinical characteristics, post-treatment data,
mortality, and follow-up data of the two groups were analyzed.
\textbf{Results:} The total effective rate of Group A was higher than
that of Group B (82.56\% versus 65.52\%, P \textless{} 0.05). The left
ventricular ejection fraction (LVEF) was improved in both groups (11.14
\selectlanguage{ngerman}± 10.16 versus 7.15 ± 11.18, P = 0.004). The left ventricular
end-diastolic/-systolic diameter (LVEDD/LVESD) in Group A decreased more
than that in Group B (3.58 ± 9.21 versus 0.27 ± 14.44, P=0.026; 4.21 ±
8.15 versus 1.14 ± 12.12, P=0.016, respectively). The N-terminal
prohormone of B-type natriuretic peptide (NT-proBNP) in both groups
decreased (1305.65 ± 2000.85 versus 675.91 ± 1649.84, P=0.012). The
systolic and diastolic blood pressure (SBP/DBP) in Group A decreased
more than that in Group B (13.13 ± 23.98 versus 1.81 ± 10.89, P
\textless{} 0.001; 8.28 ± 17.79 versus 2.37 ± 11.41, P = 0.005,
respectively). Liver and renal insufficiency, hyperkalemia, symptomatic
hypotension, Angioedema or acute heart failure have no statistical
differences between the two groups. \textbf{Conclusion:}
Sacubitril/valsartan can effectively improve the cardiac function of CHF
patients after CVS by increasing LVEF, reducing LVEDD, LVESD, NT-proBNP
and BP, with good safety.%
\end{abstract}\selectlanguage{ngerman}%



\sloppy


\textbf{Hosted file}

\verb`manuscript.doc`  available at \url{https://authorea.com/users/492103/articles/574897-benefits-of-sacubitril-valsartan-use-in-patients-with-chronic-heart-failure-after-cardiac-valve-surgery-a-single-center-retrospective-study}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Fig-1/Fig-1}

\end{center}
\end{figure}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Fig-2/Fig-2}

\end{center}
\end{figure}

\textbf{Hosted file}

\verb`Table 1.doc`  available at \url{https://authorea.com/users/492103/articles/574897-benefits-of-sacubitril-valsartan-use-in-patients-with-chronic-heart-failure-after-cardiac-valve-surgery-a-single-center-retrospective-study}

\textbf{Hosted file}

\verb`Table 2.doc`  available at \url{https://authorea.com/users/492103/articles/574897-benefits-of-sacubitril-valsartan-use-in-patients-with-chronic-heart-failure-after-cardiac-valve-surgery-a-single-center-retrospective-study}

\textbf{Hosted file}

\verb`Table 3.doc`  available at \url{https://authorea.com/users/492103/articles/574897-benefits-of-sacubitril-valsartan-use-in-patients-with-chronic-heart-failure-after-cardiac-valve-surgery-a-single-center-retrospective-study}

\textbf{Hosted file}

\verb`Table 4.doc`  available at \url{https://authorea.com/users/492103/articles/574897-benefits-of-sacubitril-valsartan-use-in-patients-with-chronic-heart-failure-after-cardiac-valve-surgery-a-single-center-retrospective-study}

\textbf{Hosted file}

\verb`Table 5.doc`  available at \url{https://authorea.com/users/492103/articles/574897-benefits-of-sacubitril-valsartan-use-in-patients-with-chronic-heart-failure-after-cardiac-valve-surgery-a-single-center-retrospective-study}

\selectlanguage{english}
\FloatBarrier
\end{document}

